Sodium channel modulators for the treatment of pain

1. A compound of Formula (I),

or a pharmaceutically acceptable salt, or a stereoisomeric or tautomeric form thereof, wherein:

Z is —O— or —S—;

Y is —X—C(═O)NR 4 R 5 , (CH 2 ) 3 —NR 9 R 10 , or 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-(2-yl or 3-yl);

X is (C 6 -C 10 )aryl or 5- or 6-membered heteroaryl;

R 1 is a partially unsaturated or aromatic 5- or 6-membered heterocycle;

R 2 is independently at each occurrence —F, —Cl, —Br, —CH 3 or —CN;

R 3 is independently at each occurrence —H, —F, —Cl, —Br, —CF 3 , —OCF 3 , —CN, (C 1 -C 12 )alkyl, or (C 1 -C 12 )alkoxy;

R 4 and R 5 are each independently H, (C 1 -C 9 )alkyl, or (C 4 -C 12 )cycloalkyl; with the proviso that:

R 4 and R 5 are not both H; and

at least one of R 4 and R 5 independently is substituted with 1 or 2 substituents selected from the group consisting of —CO 2 H, —CO 2 R 6 , —CN, —OH, —CONR 7 R 8 , and —NR 7 R 8 ; wherein:

R 6 is (C 1 -C 12 )alkyl;

R 7 and R 8 are each independently H, (C 1 -C 12 )alkyl, or R 7 and R 8 together form a 4- to 7-membered heterocycloalkyl ring;

R 9 is (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, pyrazolyl or pyridinyl; wherein R 9 is optionally further substituted with 1 or 2 substituents selected from the group consisting of —COOH, —COOR 11 , —CONR 11 R 12 , —SO 2 R 11 , —SO 2 NR 11 R 12 , —OH, —CN, —OR 11 , and —NR 11 R 12 ; wherein R 11 and R 12 may form a 6 membered heterocycloalkyl ring

R 10 is R 11 , —COR 11 , —COOR 11 , —SO 2 R 11 , 5-methyl-2-oxo-1,3-dioxol-4-yl,

—COO—CH(CH 3 )OCOCH(CH 3 ) 2 ; or R 9 and R 10 together form a piperazinone or a 4- to 8-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring is substituted with 1 or 2 substituents selected from the group consisting of —COOH, —COOR 11 , —CH 2 —COOR 11 , —OH, —NH 2 , —CN, and (C 1 -C 8 )alkoxy;

R 11 and R 12 are independently H or (C 1 -C 6 )alkyl, optionally substituted with 4- to 8-membered heterocycloalkyl ring; and

m and n are each independently 1, 2, 3, or 4.

2. The compound of claim 1 , wherein Y is —(CH 2 ) 3 —NR 9 R 10 .

3. The compound of claim 1 , wherein R 1 is an aromatic 5- or 6-membered heterocycle, with 1-3 heteroatoms independently selected from the group consisting of N, O, and S.

4. The compound of claim 1 , wherein R 2 is independently at each occurrence —F or —Cl.

5. The compound of claim 1 , wherein n is 1, 2, or 3.

6. The compound of claim 1 , wherein Z is —O.

7. The compound of claim 1 , wherein R 3 is independently at each occurrence —H, —F, —Cl, or —Br.

8. The compound of claim 1 , wherein m is 1, 2, or 3.

9. The compound of claim 1 , wherein R 9 is (C 1 -C 6 )alkyl; wherein R 9 is optionally further substituted with 1 or 2 substituents selected from the group consisting of —COOH, —Come, —CONH 2 , and —NH 2 .

10. The compound of claim 1 , wherein R 10 is —H, —COMe, —Coot.

11. The compound of claim 1 , wherein R 9 and R 10 together form a 4 to 8 membered heterocycloalkyl ring, wherein said heterocycloalkyl ring is substituted with 1 or 2 groups selected from the group consisting of —COOH, —Come, —Coot, —CH 2 —COOH, and —NH 2 .

12. The compound of claim 1 , wherein R 9 and R 10 together form a piperidine substituted with 1 or 2 groups selected from the group consisting of —COOH, —Come, —Coot, —CH 2 —COOH, —CH 2 —COOMe, —CH 2 —COOEt, and —NH 2 .

13. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt, or tautomeric form thereof, and a pharmaceutically acceptable carrier.

14. The composition of claim 13 , wherein the composition is suitable for topical, oral, subcutaneous, or intravenous administration.

15. A method for treatment of pain in a subject, wherein the method comprises administering to the subject in need of such treatment a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, or tautomeric form thereof.

16. The method of claim 15 , wherein the therapeutically effective amount to alleviate pain in a subject is at a dose between 0.1 mg/kg and 1,000 mg/kg, at a dose between 0.5 mg/kg and 100 mg/kg, or at a dose between 1 mg/kg to 50 mg/kg.

17. The method of claim 15 , wherein the pain comprises or results from painful conditions comprising: nociceptive pain, myofascial pain; neuropathic pain, pain with nociceptive and neuropathic components; visceral pain; headache pain; CRPS; CRPS type I; CRPS type II; RSD; reflex neurovascular dystrophy; reflex dystrophy; sympathetically maintained pain syndrome; causalgia; Sudeck atrophy of bone; algoneurodystrophy; shoulder hand syndrome; post-traumatic dystrophy; autonomic dysfunction; autoimmune-related pain; inflammation-related pain; cancer-related pain; phantom limb pain; chronic fatigue syndrome; post-operative pain; spinal cord injury pain; central post-stroke pain; radiculopathy; sensitivity to temperature, light touch or color change to the skin (allodynia); pain from hyperthermic or hypothermic conditions; diabetic neuropathy, luetic neuropathy, postherpetic neuralgia, trigeminal neuralgia); chronic pain; or acute pain.

18. The method of claim 15 , wherein the compound is a voltage-gated sodium channel inhibitor of NaV1.7.

19. The method of claim 15 , wherein the pain is neuropathic or inflammatory pain.

20. The method of claim 17 , wherein the nociceptive pain is pain resulting from or associated with a cut or contusion of the skin, a chemical or thermal burn, osteoarthritis, rheumatoid arthritis or tendonitis.

21. The method of claim 17 , wherein the neuropathic pain is pain resulting from or associated with stroke, diabetic neuropathy, luetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, fibromyalgia, or painful neuropathy induced iatrogenically by drugs.

22. The method of claim 17 , wherein the headache pain is migraine headache pain.